Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

About Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: N/A
Symbol: NASDAQ:RTTR
CUSIP: N/A
Web: www.ritterpharmaceuticals.com

Capitalization:

Market Cap: $7.41 million
Outstanding Shares: 14,756,000

Average Prices:

50 Day Moving Avg: $0.55
200 Day Moving Avg: $0.55
52 Week Range: $0.48 - $3.75

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -0.85
P/E Growth: 0.0000

Sales & Book Value:

Annual Revenue: N/A
Price / Sales: N/A
Book Value: $0.20 per share
Price / Book: 2.46

Profitability:

EBIDTA: ($14,790,000.00)
Return on Equity: -399.81%
Return on Assets: -218.40%

Debt:

Current Ratio: 2.07%
Quick Ratio: 2.07%

Misc:

Average Volume: 141,843 shs.
Beta: 0.65
Short Ratio: 2.76

Frequently Asked Questions for Ritter Pharmaceuticals (NASDAQ:RTTR)

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) announced its earnings results on Monday, August, 7th. The company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.00. View Ritter Pharmaceuticals' Earnings History.

Where is Ritter Pharmaceuticals' stock going? Where will Ritter Pharmaceuticals' stock price be in 2017?

5 brokerages have issued 12 month price objectives for Ritter Pharmaceuticals' stock. Their predictions range from $1.50 to $9.00. On average, they anticipate Ritter Pharmaceuticals' share price to reach $5.70 in the next year. View Analyst Ratings for Ritter Pharmaceuticals.

Who are some of Ritter Pharmaceuticals' key competitors?

Some companies that are related to Ritter Pharmaceuticals include Celsion Corporation (CLSN), Evgen Pharma PLC (EVG), Proteome Sciences plc (PRM), Bio Blast Pharma (ORPN), Kitov Pharmaceuticals Holdings (KTOV), Opexa Therapeutics (ACER), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX), Biotie Therapies Corp (BITI), Cynapsus Therapeutics (CYNA), Dyax Corp. (DYAX), Kythera Biopharmaceuticals (KYTH), Medivation (MDVN), MEI Pharma (MSHL), Nexvet Biopharma plc (NVET), NPS Pharmaceuticals (NPSP) and Ocata Therapeutics (OCAT).

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:

Ira E. Ritter, Executive Chairman of the Board, Chief Strategic Officer
Michael D. Step, Chief Executive Officer, Director
Ellen Mochizuki, Vice President - Finance
Andrew J. Ritter, President, Founder, Director
Noah J. Doyle, Independent Director
Matthew W. Foehr, Independent Director
Paul V. Maier, Independent Director
William M. Merino Ph.D., Independent Director
Gerald T. Proehl, Independent Director

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

How do I buy Ritter Pharmaceuticals stock?

Shares of Ritter Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of Ritter Pharmaceuticals stock can currently be purchased for approximately $0.50.

MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		104 (Vote Outperform)
Underperform Votes:		91 (Vote Underperform)
Total Votes:		195

MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Ritter Pharmaceuticals (NASDAQ:RTTR) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.80)
Consensus Price Target:	$5.70 (1,035.01% upside)

Analysts' Ratings History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
8/8/2017	Chardan Capital	Lower Price Target	Buy -> Buy	$3.50 -> $1.50	Medium
8/4/2017	Maxim Group	Reiterated Rating	Hold		Low
3/7/2017	Aegis	Reiterated Rating	Buy		Medium
1/4/2017	Rodman & Renshaw	Initiated Coverage	Buy	$7.00	N/A
12/12/2016	Roth Capital	Initiated Coverage	Buy	$6.00	N/A

(Data available from 9/25/2015 forward)

Earnings History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Earnings by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Earnings History by Quarter for Ritter Pharmaceuticals (NASDAQ RTTR)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
8/7/2017	Q2 2017	($0.15)	($0.14)	View	N/A
5/9/2017	Q1 2017	($0.38)	($0.14)	View	N/A
2/27/2017	Q4 2016	($0.35)	($0.74)	View	N/A
11/7/2016	Q3 2016	($0.50)	($0.41)	View	N/A
8/8/2016	Q216	($0.34)	($0.48)	View	N/A
5/9/2016		($0.32)	($0.36)	View	N/A
3/21/2016	Q4	($0.34)	($0.27)	View	N/A
11/17/2015	Q315		($0.40)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Ritter Pharmaceuticals (NASDAQ:RTTR)

Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Dividend History for Ritter Pharmaceuticals (NASDAQ:RTTR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Insider Ownership Percentage: 30.40%
Institutional Ownership Percentage: 7.55%

Institutional Ownership by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/18/2017	Matthew W Foehr	Director	Buy	18,000	$0.62	$11,160.00
5/11/2017	Michael D Step	CEO	Buy	13,000	$0.62	$8,060.00
2/27/2017	Michael D Step	CEO	Buy	10,000	$2.65	$26,500.00
2/22/2016	Andrew J Ritter	Major Shareholder	Buy	6,250	$1.60	$10,000.00
1/8/2016	Matthew W Foehr	Director	Buy	13,000	$1.64	$21,320.00
1/7/2016	Michael D Step	CEO	Buy	27,000	$1.48	$39,960.00
6/24/2015	Gerald T Proehl	Director	Buy	50,000	$5.00	$250,000.00
6/24/2015	Javelin Venture Partners, L.P.	Major Shareholder	Buy	800,000	$5.00	$4,000,000.00

(Data available from 1/1/2013 forward)

Headline Trends for Ritter Pharmaceuticals (NASDAQ:RTTR) Latest Headlines for Ritter Pharmaceuticals (NASDAQ:RTTR)

Source:

Date	Headline
	Ritter Pharmaceuticals, Inc. (RTTR) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - September 24 at 2:08 PM
	Zacks: Analysts Anticipate Ritter Pharmaceuticals, Inc. (RTTR) Will Post Earnings of -$0.18 Per Share www.americanbankingnews.com - September 24 at 12:18 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Downgraded by Zacks Investment Research www.americanbankingnews.com - September 23 at 6:36 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - September 16 at 7:18 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - September 9 at 8:40 AM
	Zacks Investment Research Downgrades Ritter Pharmaceuticals, Inc. (RTTR) to Hold www.americanbankingnews.com - September 7 at 8:20 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - September 5 at 9:00 PM
	Financial Comparison: Ritter Pharmaceuticals (RTTR) versus Acorda Therapeutics (ACOR) www.americanbankingnews.com - August 31 at 6:14 AM
	Zacks Investment Research Upgrades Ritter Pharmaceuticals, Inc. (RTTR) to Buy www.americanbankingnews.com - August 29 at 10:20 AM
	Ritter Pharmaceuticals (RTTR) Reports Phase 3 Plans Following End of Phase 2 Meeting with FDA on RP-G28 for LI www.streetinsider.com - August 19 at 7:11 AM
	Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance finance.yahoo.com - August 19 at 7:11 AM
	Analysts Anticipate Ritter Pharmaceuticals, Inc. (RTTR) Will Announce Earnings of -$0.17 Per Share www.americanbankingnews.com - August 17 at 6:16 PM
	Ritter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - August 11 at 11:32 PM
	Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Posts Quarterly Earnings Results, Meets Estimates www.americanbankingnews.com - August 8 at 1:36 PM
	Chardan Capital Trims Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Target Price to $1.50 www.americanbankingnews.com - August 8 at 1:20 PM
	Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - August 8 at 8:50 AM
	Ritter Pharma (RTTR) Reports FDA to Schedule End-of-Phase 2 Meetings; Granted 3 New Patents for RP-G28 ... - StreetInsider.com www.streetinsider.com - August 8 at 6:48 AM
	Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update feeds.benzinga.com - August 7 at 7:16 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Rating Reiterated by Maxim Group www.americanbankingnews.com - August 4 at 3:48 PM
	Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms finance.yahoo.com - August 4 at 7:46 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - July 17 at 8:14 PM
	Maxim Group Reiterates "Hold" Rating for Ritter Pharmaceuticals, Inc. (RTTR) www.americanbankingnews.com - July 9 at 6:02 PM
	Ritter Pharmaceuticals, Inc. (RTTR) Expected to Post Earnings of -$0.19 Per Share www.americanbankingnews.com - July 6 at 10:30 AM
	Ritter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - June 20 at 8:52 PM
	Ritter Pharmaceuticals, Inc. (RTTR) Expected to Announce Earnings of -$0.19 Per Share www.americanbankingnews.com - June 12 at 10:24 AM
	Ritter Pharmaceuticals Inc (RTTR) Short Interest Update www.americanbankingnews.com - May 28 at 7:12 AM
	Ritter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Buy" by Analysts www.americanbankingnews.com - May 26 at 9:05 PM
	Ritter Pharmaceuticals Inc (RTTR) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - May 23 at 7:18 AM
	Ritter Pharmaceuticals Inc (RTTR) Director Matthew W. Foehr Acquires 18,000 Shares www.americanbankingnews.com - May 18 at 4:54 PM
	-$0.27 Earnings Per Share Expected for Ritter Pharmaceuticals Inc (RTTR) This Quarter www.americanbankingnews.com - May 15 at 10:30 PM
	Ritter Pharmaceuticals Inc (RTTR) Releases Quarterly Earnings Results, Beats Expectations By $0.24 EPS www.americanbankingnews.com - May 10 at 4:56 PM
	Ritter Pharmaceuticals Inc (RTTR) Rating Reiterated by Maxim Group www.americanbankingnews.com - May 9 at 11:36 PM
	Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP- www.nasdaq.com - May 4 at 12:21 AM
	Ritter Pharmaceuticals (RTTR) Getting Positive Press Coverage, Analysis Finds www.americanbankingnews.com - May 3 at 1:03 AM
	Ritter Pharma (RTTR) Announces New Patents for its Lactose Intolerance Treatment, RP-G28; Provides an Update on ... - StreetInsider.com www.streetinsider.com - May 2 at 5:27 PM
	Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3 finance.yahoo.com - May 2 at 5:27 PM
	Ritter Pharmaceuticals Inc (RTTR) Receives Consensus Rating of "Buy" from Analysts www.americanbankingnews.com - May 1 at 10:32 PM
	Exclusive: Ritter Pharmaceuticals CEO Talks Stock Scare, Indication Niche feeds.benzinga.com - April 28 at 10:42 AM
	Ritter Pharmaceuticals (RTTR) Given News Sentiment Score of 0.07 www.americanbankingnews.com - April 27 at 11:26 PM
	Ritter Pharmaceuticals (RTTR) Receiving Somewhat Negative News Coverage, Study Shows www.americanbankingnews.com - April 24 at 11:20 AM
	Ritter Pharmaceuticals (RTTR) Given News Impact Score of 0.37 www.americanbankingnews.com - April 18 at 5:48 PM
	Ritter Pharmaceuticals (RTTR) Earning Somewhat Favorable Media Coverage, AlphaOne Reports www.americanbankingnews.com - April 14 at 10:23 PM
	Ritter Pharma (RTTR) Says FDA Agrees to Schedule End of Phase 2 Meeting - StreetInsider.com www.streetinsider.com - April 12 at 6:22 PM
	Ritter Pharmaceuticals Inc (RTTR) Receives "Hold" Rating from Maxim Group www.americanbankingnews.com - April 12 at 4:36 PM
	Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities finance.yahoo.com - April 12 at 1:21 PM
	Ritter Pharmaceuticals Inc (RTTR) Price Target Cut to $3.50 by Analysts at Chardan Capital www.americanbankingnews.com - April 5 at 10:16 AM
	Ritter Pharmaceuticals Inc (RTTR) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 4 at 6:09 PM
	Ritter Pharmaceuticals Inc (RTTR) PT Lowered to $3.50 www.americanbankingnews.com - March 30 at 8:53 AM
	Ritter Pharmaceuticals (RTTR) Flails on Study Results www.baystreet.ca - March 29 at 9:25 PM
	Ritter Pharmaceuticals downgraded by Maxim Group finance.yahoo.com - March 29 at 9:25 PM